About
Steve Landau is the Chief of Development of GV20 Oncotherapy. He has been in the biotechnology field for approximately 20 years. He previously served as Director of Clinical and Scientific Evaluation Department at Healthcare Ventures and held senior managerial positions like Chief Medical Officer at multiple innovative new drugs R&D companies. Dr. Landau has established new clinical programs in the areas of gastroenterology, metabolism, inflammation, oncology and central nervous system disorders. Moreover, he successfully facilitated FDA approval of a monoclonal antibody in Crohn’s Disease and Ulcerative Colitis. Dr. Landau completed his post graduate training at the Beth Israel Hospital and the Brigham and Women’s Hospital in Boston, and was Assistant Professor of Medicine at the University of Vermont. Dr. Landau is board certified.
Position in the VCSift Database
- • 1 investors hold the Chief of Development role in VCSift. Steve Landau is one of them.
- • 21 investors are based in Wellesley Hills, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Wellesley Hills, US
Contact Information
Find more investors like Steve
Search Investors